Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia While on Treatment with Imatinib Mesylate for 65 Months

Michael, Michalis; Antoniades, Marios; Lemesiou, Elena; Papaminas, Nicandros; Melanthiou, Frederiki

doi:10.1634/theoncologist.2009-0165

Cited by 19 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before the arrival of the TKIs, patients with CML preceding MM were treated with different agents including busulfan, hydroxyurea, interferon and cytarabine. A CML patient treated with TKIs has been reported to have developed MM after 64 months of imatinib therapy [8] , similarly to the case we are presenting.…”

Section: Discussion and Literature Reviewsupporting

confidence: 75%

Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series

AlShehry¹,

Al-Huneini²,

Lipton³

et al. 2015

Acta Haematol

View full text Add to dashboard Cite

Lymphoproliferative disorders presenting simultaneously with or subsequent to the occurrence of chronic myeloid leukemia (CML) have rarely been reported. Herein, we report 8 cases of a variety of lymphoproliferative conditions associated with CML at different times during the course of the disease. All 8 patients were treated with tyrosine kinase inhibitors at some point during the course of their illness. The literature regarding the uncommon association of these apparently unrelated disorders is reviewed as well as the possible underlying mechanisms that could be associated with this phenomenon.

show abstract

Section: Discussion and Literature Reviewsupporting

confidence: 75%

Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series

AlShehry¹,

Al-Huneini²,

Lipton³

et al. 2015

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Literature review shows case reports of new hematopathologic neoplasms occurring after treatment of an initial hematologic malignancy; this can be a single additional neoplasm or up to three new neoplasms after treatment. Examples of such cases include multiple myeloma after treatment for CML with imatinib [ 9 , 10 , 14 , 15 ] and a unique case of three coexisting lymphomas including primary cutaneous marginal zone B cell lymphoma (MZBL), nodal Epstein-Barr virus- (EBV-) associated classic Hodgkin's lymphoma (cHL), and peripheral T cell lymphoma after treatment of nodal T cell lymphoma thirty years prior [ 16 ]. The case that we present is exceptionally unique in the fact that it is the only report of three simultaneous hematopathologic neoplasms diagnosed in a patient with no previous exposure to chemotherapy or radiation.…”

Section: Introductionmentioning

confidence: 99%

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder

Maerki

Katava

Siegel

et al. 2014

Case Reports in Hematology

View full text Add to dashboard Cite

Background. Multiple articles discuss the rare incidence and potential causes of second hematologic disorders arising after treatment of Chronic Myelogenous Leukemia (CML), leading to the theory of imatinib, the current treatment regimen for CML, as a possible trigger for the development of secondary neoplasms. Our case eliminates the possibility of imatinib as the sole cause since our patient received a diagnosis of simultaneous plasma cell myeloma, CML, and a Jak2 mutation positive myeloproliferative disorder (MPD) arising de novo, prior to any treatment. We will further investigate into alternative theories as potential causes for multiple hematopathologic disorders. Case Report. There are currently no reported cases with the diagnosis of simultaneous plasma cell myeloma, chronic myelogenous leukemia, and Jak2 positive myeloproliferative disorder. We present a case of a 77-year-old male who was discovered to have these three concurring hematopathologic diagnoses. Our review of the literature includes a look at potential associations linking the three coexisting hematologic entities. Conclusion. The mechanism resulting in simultaneous malignancies is most likely multifactorial and potentially includes factors specific to the host, continuous stimulation of the immune system, previous chemotherapy or radiation, a potential common pluripotent stem cell, or, lastly, preexisting myeloma which may increase the susceptibility of additional malignancies.

show abstract

“…Though originating from different cell origins, case reports published over the years have described patients with the coexistence of CML and MM or other paraproteinemias. In some cases, the CML diagnosis and tyrosine kinase inhibitor (TKI) treatment preceded the diagnosis of MM [5][6][7][8][9][10][11][12], raising concern that TKI treatment may have contributed toward MM development. In other cases, the MM preceded the diagnosis of CML [13][14][15][16][17][18], while a few had both diseases simultaneously diagnosed [19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia

et al. 2022

View full text Add to dashboard Cite

Introduction: Data regarding the prevalence of paraproteinemia in patients with chronic myeloid leukemia (CML) are lacking. Methods: To evaluate for paraproteinemia prevalence we undertook this cross-sectional study among consecutive chronic-phase CML patients. Complete blood count, chemistry, immunoglobulins, serum-free light chains, serum-protein electrophoresis and immunofixation were collected. Further analyses evaluated whether various patient, disease and treatment-related variables are associated with paraproteinemia. Results: One hundred patients, median age 63.5 (IQR 48.1-72) years were recruited. Median time from CML diagnosis to enrollment was 6.3 (IQR 2.3-11.3) years. Monoclonal-protein was detected in eight patients (8%), diagnosed with: smoldering multiple myeloma (SMM, n=2) and low-risk monoclonal gammopathy of undetermined significance (MGUS, n=6). Six patients were on tyrosine kinase inhibitor treatment, two were in treatment-free-remission. The only covariate associated with paraproteinemia was the presence of anemia, albeit with borderline statistical significance in univariate analysis (p=0.053) and when adjusted for age (p=0.056). Conclusions: In this largest study so far describing the prevalence of paraproteinemia among CML patients, we found MGUS prevalence to be higher than the 3.2% expected prevalence in the general-population above 50 years and a non-negligible prevalence of SMM (2%). Screening for paraproteinemia in CML patients, especially in the presence of anemia, should be considered.

show abstract

Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia While on Treatment with Imatinib Mesylate for 65 Months

Cited by 19 publications

References 12 publications

Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series

Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder

Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia

Contact Info

Product

Resources

About